DAFTAR PUSTAKA

1. Bakta IM. Limfoma Maligna. dalam: Hematologi Klinik Ringkas. Denpasar; 2006. 192–

219.

2. Komite Penanggulangan Kanker Nasional. Panduan Penatalaksanaan Limfoma Non

Hodgin.Jakarta;2016.1-9

3. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. Infodatin-Limfoma

2015. Vol. 1, Infodatin. 2015. p. 1–6.

4. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet.2012;

380(9844):848–57.

5. Bertrand C, Eric L, Josette B. et al. Rituximab Vs CHOP Alone in Elderly Patients With

Diffuse Large B Cell Lymphoma. N Eng J Med. 2002;346(4):235–42.

6. Nishimori H, Matsuo K, Maeda Y, et al. The effect of adding rituximab to CHOP-based

therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: A

propensity score matching analysis. Int J Hematol. 2009;89(3):326–31.

7. Reksodiputro AH. Limfoma Non Hodgin (LNH). dalam : Buku Ajar Ilmu Penyakit Dalam

Alwi I, editor. Jakarta; 2014. p. 2980.

8. Oehadian A. Pendekatan diagnosis limfadenopati. CKD-209.2013;(40)10:727-32

9. Guideline P. Practice Guideline Guidelines for the diagnosis and treatment of follicular

lymphoma in China Treatment of FL Treatment indicators. Cancer Bio Med. 2013;(3):36–

42.

10. Ren Y-R, Jin Y-D, Zhang Z-H,et al. Rituximab Treatment Strategy for Patients with

Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and
 Meta-Analysis. Chin Med J (Engl). 2015;128(3):378. A

11. Excellence C. Non-Hodgkin’s lymphoma : Diagnosis and management NICE guideline

NG52:2016;1-180

12. Frederiksen JK, Sharma M, Casulo C, et al. Systematic review of the effectiveness of fine-

needle aspiration and/or core needle biopsy for subclassifying lymphoma. Arch Pathol

Lab Med. 2015;139(2):245–51.

13. Study R, Unit IN, Service B. Prognostic Factors of Non-Hodgkin Lymphoma :

Retrospective Study in Unit Blood Service of the. 2015;6.

14. Pishko A, Nasta SD. The role of novel immunotherapies in non-Hodgkin lymphoma.

Transl Cancer Res. 2017;6(1):93–103.

15. Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response

evaluation criteria in lymphoma (RECIL 2017). Ann Oncol Off J Eur Soc Med Oncol.

2017;28(7):1436–47.

16. Persijn V, Meerten EL, Gelderblom H, et al. RECIST revised: Implications for the

radiologist. A review article on the modified RECIST guideline. Eur Radiol.

2010;20(6):1456–67.